Nuvectis Pharma, Inc.
NVCT· Nasdaq
Released Aug 5, 2025, before the open
10-Q filed Aug 5, 2025, 36 days after period end · 0001558370-25-010203
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$6.33M | -$4.43M | -$5.71M | -$3.57M |
| EPS Diluted | -$0.30 | -$0.26 | -$0.38 | -$0.28 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nuvectis Pharma, Inc. · CIK 1875558 · Engraved from SEC EDGAR